Wits University Research Redefines Drug-Resistant TB Care Worldwide
The University of the Witwatersrand (Wits) has once again demonstrated South Africa’s capacity to lead transformative medical research. A landmark clinical trial known as BEAT Tuberculosis, coordinated through Wits’ Clinical Health Research Unit (CHRU), has produced findings published this week in the New England Journal of Medicine that are already reshaping international standards for treating drug-resistant tuberculosis.
Conducted at the Isango Lethemba TB Research Unit in Gqeberha and the King Dinizulu Hospital Complex in Durban, the study enrolled more than 400 participants during the height of the COVID-19 pandemic. It tested a streamlined six-month regimen using four to five oral medications, including bedaquiline and delamanid, against the previous nine-month standard involving seven drugs. The results showed comparable efficacy with significantly improved safety and tolerability.
Addressing South Africa’s Enduring TB Burden
South Africa continues to face one of the world’s highest tuberculosis burdens. In 2024 alone, an estimated 249,000 people developed active TB, and 54,000 died from the disease, according to the National Department of Health. Drug-resistant forms of the disease have long posed particular challenges because of lengthy, toxic regimens that are difficult for patients to complete.
Wits researchers, working in close partnership with the National Department of Health and funded by USAID, designed the BEAT Tuberculosis trial to test whether shorter, all-oral regimens could deliver better outcomes while remaining practical in resource-limited settings. The trial deliberately included children, pregnant women and breastfeeding mothers—groups traditionally excluded from TB research—making its findings directly applicable to entire families.
Key Findings and Clinical Impact
The BEAT Tuberculosis regimen proved non-inferior to the standard of care while offering a markedly better safety profile. Participants experienced fewer severe side effects, and treatment completion rates improved because the shorter duration reduced the burden on patients and health systems alike.
Principal investigator Dr Francesca Conradie of the CHRU noted that the study has already influenced World Health Organization policy recommendations. South Africa’s National Clinical Advisory Committee has begun approving the regimen for pregnant women, and several provinces are rolling it out for paediatric cases. The one-size-fits-all approach means a three-year-old, teenager, mother and father can all receive treatment of similar length and composition, dramatically improving adherence.
Wits’ Leadership in Resource-Limited Research
The success of BEAT Tuberculosis underscores Wits University’s long-standing commitment to clinical research that serves communities most affected by infectious diseases. The CHRU, a division of the Wits Health Consortium, has conducted registrational trials for bedaquiline since 2008 and expanded operations across multiple provinces. This latest achievement builds on decades of work that positions South African universities as essential contributors to global health innovation.
University administrators and faculty at Wits emphasise that such studies also strengthen postgraduate training pipelines. Medical students, registrars and PhD candidates gain hands-on experience in large-scale, multi-site trials, preparing the next generation of clinician-scientists for careers both in South Africa and abroad.
Implications for Higher Education and Research Training
The publication of BEAT Tuberculosis results in the world’s premier medical journal highlights the strategic importance of sustained investment in South African higher-education research infrastructure. Universities such as Wits, Stellenbosch and the University of Cape Town continue to produce work that directly informs national policy and international guidelines.
Academic leaders note that trials like this create opportunities for interdisciplinary collaboration across medicine, public health, data science and health economics. They also generate valuable datasets that can support further studies on treatment adherence, cost-effectiveness and long-term outcomes—areas ripe for future postgraduate research.
Global Recognition and Policy Change
International bodies have cited BEAT Tuberculosis as a model for inclusive trial design. The findings have prompted updates to treatment protocols in multiple countries, particularly for vulnerable populations previously left behind. South African researchers are now advising ministries of health across the continent on implementation strategies.
Professor Norbert Ndjeka, Chief Director of TB Control and Management at the National Department of Health, described the achievement as exceptional: the study not only produced world-class evidence but is being implemented progressively across South Africa and globally.
Photo by Greg Rosenke on Unsplash
Challenges and the Road Ahead
Despite the breakthrough, significant hurdles remain. Scaling the new regimen nationwide requires continued training of healthcare workers, reliable drug supply chains and robust monitoring systems. Wits researchers are already planning follow-up studies to assess real-world effectiveness and to explore even shorter regimens.
University leaders stress the need for ongoing government and international funding to maintain South Africa’s competitive edge in TB research. Partnerships between higher-education institutions, the National Department of Health and global funders remain critical.
Looking Forward: South Africa’s Research Ecosystem
The BEAT Tuberculosis trial exemplifies how South African universities can drive solutions to some of the world’s most pressing health challenges. As Wits and its partners continue to publish in top-tier journals, they also contribute to the training of researchers who will shape the next decade of TB control efforts.
For academics, administrators and aspiring researchers, the study serves as both inspiration and a reminder of the tangible impact that rigorous, community-engaged research can achieve when supported by strong institutional frameworks.
